FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966366851> ?p ?o ?g. }

• W1966366851 endingPage "1085" @default.
• W1966366851 startingPage "1075" @default.
• W1966366851 abstract "There is a growing interest in cell-based therapies in T2DM as β-cell failure is progressive and inexorable with the advancing duration of disease. This prospective, randomized, single-blinded placebo-controlled study evaluates the efficacy and safety of autologous bone marrow-derived stem cell transplantation (ABMSCT) in T2DM. Twenty-one patients with triple oral antidiabetic drug failure and requiring insulin ≥0.4 IU per kg per day with HbA1c <7.5% were randomly assigned to an intervention ( n = 11) and control group ( n = 10) and followed for 12 months. Patients in the intervention group received ABMSCT through a targeted approach, and after 12 weeks, a second dose of stem cells was administered through the antecubital vein after mobilization with G-CSF, while the control group underwent a sham procedure. The primary end point was a reduction in insulin requirement by ≥50% from baseline while maintaining HbA1c <7%. Nine out of the 11 (82%) patients in the intervention group achieved the primary end point, whereas none of the patients in the control group did over the study period ( p = 0.002). The insulin requirement decreased by 66.7% in the intervention group from 42.0 (31.0-64.0) IU per day to 14.0 (0.0-30.0) IU per day ( p = 0.011), while in controls it decreased by 32.1% from 40.5 (31.8-44.3) IU per day to 27.5 (23.5-33.3) IU per day ( p = 0.008) at 12 months. The reduction in insulin requirement was significantly more in the intervention group compared to controls at both 6 ( p = 0.001) and 12 months ( p = 0.004). There was a modest but nonsignificant increase in HbA1c (%) in cases from 6.9% (6.4-7.2%) to 7.1% (6.6-7.5%) as well as in controls from 6.9% (6.2-7.0%) to 7.0% (6.9-7.5%). Ten out of 11 (91%) patients could maintain HbA1c <7% in the intervention group, whereas 6 out of 10 did (60%) in the control group ( p = 0.167). The glucagon-stimulated C-peptide significantly increased in treated cases compared to controls ( p = 0.036). The decrease in insulin requirement positively correlated with stimulated C-peptide ( r = 0.8, p = 0.001). In conclusion, ABMSCT results in a significant decrease in the insulin dose requirement along with an improvement in the stimulated C-peptide levels in T2DM. However, a greater number of patients with a longer duration of follow-up are required to substantiate these observations." @default.
• W1966366851 created "2016-06-24" @default.
• W1966366851 creator A5008804538 @default.
• W1966366851 creator A5022535224 @default.
• W1966366851 creator A5026048488 @default.
• W1966366851 creator A5033387018 @default.
• W1966366851 creator A5054334935 @default.
• W1966366851 creator A5060183060 @default.
• W1966366851 creator A5074455288 @default.
• W1966366851 creator A5075185387 @default.
• W1966366851 creator A5081390575 @default.
• W1966366851 creator A5087479414 @default.
• W1966366851 date "2014-09-01" @default.
• W1966366851 modified "2023-10-09" @default.
• W1966366851 title "Efficacy and Safety of Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients with Type 2 Diabetes Mellitus: A Randomized Placebo-Controlled Study" @default.
• W1966366851 cites W1972392301 @default.
• W1966366851 cites W1981456793 @default.
• W1966366851 cites W1990363917 @default.
• W1966366851 cites W1993902386 @default.
• W1966366851 cites W1997801265 @default.
• W1966366851 cites W2009600260 @default.
• W1966366851 cites W2025779728 @default.
• W1966366851 cites W2028174844 @default.
• W1966366851 cites W2035686191 @default.
• W1966366851 cites W2044570743 @default.
• W1966366851 cites W2057190776 @default.
• W1966366851 cites W2063259644 @default.
• W1966366851 cites W2070990833 @default.
• W1966366851 cites W2084826636 @default.
• W1966366851 cites W2085618141 @default.
• W1966366851 cites W2091526175 @default.
• W1966366851 cites W2091594596 @default.
• W1966366851 cites W2095240021 @default.
• W1966366851 cites W2096846676 @default.
• W1966366851 cites W2112270957 @default.
• W1966366851 cites W2121264929 @default.
• W1966366851 cites W2127125241 @default.
• W1966366851 cites W2130576704 @default.
• W1966366851 cites W2134315188 @default.
• W1966366851 cites W2147452038 @default.
• W1966366851 cites W2159228440 @default.
• W1966366851 cites W2159999899 @default.
• W1966366851 cites W2169071674 @default.
• W1966366851 cites W2337454357 @default.
• W1966366851 cites W4254695749 @default.
• W1966366851 doi "https://doi.org/10.3727/096368913x665576" @default.
• W1966366851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23561959" @default.
• W1966366851 hasPublicationYear "2014" @default.
• W1966366851 type Work @default.
• W1966366851 sameAs 1966366851 @default.
• W1966366851 citedByCount "81" @default.
• W1966366851 countsByYear W19663668512013 @default.
• W1966366851 countsByYear W19663668512014 @default.
• W1966366851 countsByYear W19663668512015 @default.
• W1966366851 countsByYear W19663668512016 @default.
• W1966366851 countsByYear W19663668512017 @default.
• W1966366851 countsByYear W19663668512018 @default.
• W1966366851 countsByYear W19663668512019 @default.
• W1966366851 countsByYear W19663668512020 @default.
• W1966366851 countsByYear W19663668512021 @default.
• W1966366851 countsByYear W19663668512022 @default.
• W1966366851 countsByYear W19663668512023 @default.
• W1966366851 crossrefType "journal-article" @default.
• W1966366851 hasAuthorship W1966366851A5008804538 @default.
• W1966366851 hasAuthorship W1966366851A5022535224 @default.
• W1966366851 hasAuthorship W1966366851A5026048488 @default.
• W1966366851 hasAuthorship W1966366851A5033387018 @default.
• W1966366851 hasAuthorship W1966366851A5054334935 @default.
• W1966366851 hasAuthorship W1966366851A5060183060 @default.
• W1966366851 hasAuthorship W1966366851A5074455288 @default.
• W1966366851 hasAuthorship W1966366851A5075185387 @default.
• W1966366851 hasAuthorship W1966366851A5081390575 @default.
• W1966366851 hasAuthorship W1966366851A5087479414 @default.
• W1966366851 hasConcept C126322002 @default.
• W1966366851 hasConcept C134018914 @default.
• W1966366851 hasConcept C141071460 @default.
• W1966366851 hasConcept C142724271 @default.
• W1966366851 hasConcept C168563851 @default.
• W1966366851 hasConcept C203092338 @default.
• W1966366851 hasConcept C204787440 @default.
• W1966366851 hasConcept C27081682 @default.
• W1966366851 hasConcept C2779306644 @default.
• W1966366851 hasConcept C2780007613 @default.
• W1966366851 hasConcept C28328180 @default.
• W1966366851 hasConcept C2911091166 @default.
• W1966366851 hasConcept C54355233 @default.
• W1966366851 hasConcept C555293320 @default.
• W1966366851 hasConcept C71924100 @default.
• W1966366851 hasConcept C86803240 @default.
• W1966366851 hasConceptScore W1966366851C126322002 @default.
• W1966366851 hasConceptScore W1966366851C134018914 @default.
• W1966366851 hasConceptScore W1966366851C141071460 @default.
• W1966366851 hasConceptScore W1966366851C142724271 @default.
• W1966366851 hasConceptScore W1966366851C168563851 @default.
• W1966366851 hasConceptScore W1966366851C203092338 @default.
• W1966366851 hasConceptScore W1966366851C204787440 @default.
• W1966366851 hasConceptScore W1966366851C27081682 @default.
• W1966366851 hasConceptScore W1966366851C2779306644 @default.

• next